✦ LIBER ✦

Long-term safety of botulinum toxin type A

✍ Scribed by Markus Naumann; A. Peter Moore

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 36 KB
Volume: 18
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.10495

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term botulinum toxin efficacy, safe

Long-term botulinum toxin efficacy, safety, and immunogenicity

✍ Nicte I. Mejia; Kevin Dat Vuong; Joseph Jankovic 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

## Abstract To determine the long‐term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow‐up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously

Long-term safety, efficacy, dosing, and

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

✍ Brian Berman; Lauren Seeberger; Rajeev Kumar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Short‐term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long‐term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, t

BotB (botulinum Toxin type B): Evaluatio

BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-Resistant cervical dystonia patients (preliminary study)

✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Botulinum toxin antibody type A titres a

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

✍ Dirk Dressler; Hans Bigalke 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

## Abstract In some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop. Thirteen patients (eight

Botulinum toxin type A therapy during pr

Botulinum toxin type A therapy during pregnancy

✍ William J. Newman; Thomas L. Davis; Bismal B. Padaliya; Cassondra D. Covington; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB

## Abstract Injection with botulinum toxin type A (Botox) is a safe and efficacious treatment for idiopathic cervical dystonia. We present the first case report of clinical Botox treatment during pregnancy. This patient underwent four apparently uncomplicated full‐term pregnancies while receiving r

Botulinum toxin type A therapy during pr

Botulinum toxin type A therapy during pregnancy

✍ Cynthia L. Bodkin; Kenneth B. Maurer; Zbigniew K. Wszolek 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB